The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Final OS from NETTER-1: lutetium-177-DOTATATE in patients with midgut NETs
Enrique Grande, MD, MD Anderson Cancer Center Madrid, Madrid, Spain, discusses the final overall survival results of NETTER-1 (NCT01578239), a Phase III study evaluating lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors (NETs). With a median follow-up of 6.3 years, overall survival (OS), a secondary endpoint, in the intention to treat population did not reach statistical significance. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
